ArticleDiscover oncology2025
Integration of machine learning to reveal the correlation between ferroptosis and M2 macrophages in head and neck squamous cell carcinoma.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Iron homeostasis and macrophage polarization in oral squamous cell carcinoma: mechanisms and therapeutic perspectives.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
objectiveTo investigate the correlation between ferroptosis and M2 macrophages (M2Ms) in head and neck squamous cell carcinoma on the basis of multiomics data and machine learning methods.
methodsM2M infiltration was assessed via the CIBERSORT algorithm, and Kaplan‒Meier (K‒M) survival analysis was conducted with the best cutoff value. The M2M-related genes (MRGs) were identified on the basis of the interactive results of weighted gene coexpression network analysis (WGCNA) and the Spearman test. The interactions between MRGs and ferroptosis genes were subsequently pooled to investigate their functions, and the hub genes were subsequently applied to establish a scoring system (MFRS) with 101 kinds of machine learning algorithms. The model with the highest concordance index was selected, and the predictive effect was assessed via the area under the curve (AUC) of the receiver operating characteristic (ROC) curves. The correlations of MFRS with immune infiltration, tumor mutation burden (TMB), copy number variation (CNV) and clinical treatment were analyzed, and the landscape of the model genes was displayed with multiomics data. Moreover, a pancancer analysis was conducted to reveal the roles of crucial model genes in different tumors.
resultsPatients with low M2 infiltration had a better prognosis. According to Spearman and WGNCA, a total of 1551 interactive MRGs were identified, 40 of which were also associated with ferroptosis. After the 13 hub genes were obtained from STRING, 101 kinds of machine learning algorithms were applied to establish the predictive model. Among them, the model concerning lasso combined with plsRcox had the best predictive effects, with the highest average C-index value of 0.645, consisting of ALOX12B, CYBB, DDR2, DRD4, NOX4, PRKCA, RGS4, SLC2A3, SLC3A2, TIMP1 and ENPP2. Patients with low MFRSs presented longer survival times, a more active immune microenvironment and greater sensitivity to immunotherapy; nevertheless, those with high MFRSs presented better chemotherapeutic responses. PRKCA was considered a hub model gene on the basis of external validation of multiomics data, and the pancancer analysis subsequently revealed that it performs important roles in tumors.
conclusionIn this study, we constructed an MFRS model to predict patient prognosis and therapeutic response. This study also preliminarily reveals the roles of M2Ms and ferroptosis in HNSCC patients and provides potentially novel insight for treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.